Schrodinger, Inc.
Schrödinger (Nasdaq: SDGR) develops computational software and uses its platform to discover molecules for drug development and materials applications. Its software combines physics-based methods and machine learning to support molecule discovery, design, and optimization, and is licensed to biopharmaceutical and… From the company’s description.
Over the twelve months to Sep 30, 2026, Schrodinger, Inc. reported revenue of $269.20M, up 4.8% from a year earlier, and a net loss of $59.25M. Its operating margin was −49.6%, and operations used $112.58M in cash. In fiscal 2025, it reported revenue of $255.87M, up 23.3% from fiscal 2024, and a net loss of $103.27M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Schrodinger, Inc. does
In the company’s own words
Schrödinger (Nasdaq: SDGR) develops computational software and uses its platform to discover molecules for drug development and materials applications. Its software combines physics-based methods and machine learning to support molecule discovery, design, and optimization, and is licensed to biopharmaceutical and industrial companies, academic institutions, and government laboratories. Products include Glide, FEP+, LiveDesign, and Maestro; materials science applications include electronics, aerospace, semiconductors, energy, and chemicals. The company also applies its platform in collaborative drug discovery programs and proprietary programs, with collaborators pursuing research across therapeutic areas and Schrödinger advancing selected candidates through preclinical and clinical development. Its two business areas are software and drug discovery: 2025 software revenue was $199.5 million and drug discovery revenue was $56.4 million, out of $255.9 million in total revenue. As of December 31, 2025, it had 20 active collaborative drug discovery programs. Founded in 1990, Schrödinger began developing its proprietary drug pipeline in 2018. Its website is https://www.schrodinger.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1490978
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Schrodinger, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Schrodinger, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Schrodinger, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Schrodinger, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Schrodinger, Inc.'s last four quarterly filings that the numbers alone won't show?”